I DON'T CARE THAT MONEY FLOW AINT GREAT CRSPR IS ONE OF THE BEST IDEAS NOW.
As of late last year, CRISPR and Vertex started submitting exa-cel, their blood disorders candidate, to regulatory agencies in the U.S., the U.K., and Europe. The FDA aims to issue a decision on exa-cel for sickle cell disease in December and on exa-cel for beta thalassemia in March.
Data have been strong for both indications, so there's reason to be optimistic about exa-cel's future. For example, 94% of patients in the sickle cell trial remained free of pain crises for at least one full year. In the beta thalassemia trial, more than 88% didn't require blood transfusions for at least 12 straight months.
![]()
NASDAQ: CRSP
CRISPR Therapeutics
Today's Change
(1.39%) $0.61
Current Price
$44.45
CRSP
Key Data Points
Market Cap
$3B
Day's Range
$43.67 - $45.55
Potential for blockbuster revenue
Exa-cel could generate $1.7 billion in revenue in 2028, according to Evaluate Pharma, which puts it in blockbuster territory. Of course, CRISPR shares profit with Vertex, and Vertex will take the lion's share -- 60% -- since it also is making a bigger investment in the program's costs. But the potential product still represents a significant amount of revenue for CRISPR.
It's also important to note this isn't CRISPR's only near-term opportunity. The company is studying an immuno-oncology candidate in a trial that could support a regulatory submission. If all goes smoothly, this represents another potential product within the next few years.
Meanwhile, CRISPR is also generating revenue by licensing its gene-editing technology to others. This spring, Vertex bought access to the platform for use in one of its other programs, one targeting type 1 diabetes.
UPDATE- $48--------$52
Crispr Therapeutics call volume above normal and directionally bullish » 13:45 CRSP

